The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data

Genetics in Medicine

Volumn 18, Issue 6, 2016, Pages 618-626

  Wallace, Daniel F ^a,b   Subramaniam, V Nathan ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

hemochromatosis; mutations; next generation sequencing; non HFE hemochromatosis; prevalence

Indexed keywords

FERROPORTIN; HEMOJUVELIN; CATION TRANSPORT PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HAMP PROTEIN, HUMAN; HEMOCHROMATOSIS PROTEIN; HEPCIDIN; HFE PROTEIN, HUMAN; HFE2 PROTEIN, HUMAN; METAL TRANSPORTING PROTEIN 1; TFR2 PROTEIN, HUMAN; TRANSFERRIN RECEPTOR;

AFRICAN; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC DISORDER; GENETIC VARIABILITY; HEMOCHROMATOSIS; HEMOCHROMATOSIS GENE; HEREDITARY HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; NEXT GENERATION SEQUENCING; PATHOGENESIS; BLACK PERSON; FEMALE; GENETIC ASSOCIATION STUDY; GENETICS; GENOTYPE; HIGH THROUGHPUT SEQUENCING; MALE; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY;

AFRICAN CONTINENTAL ANCESTRY GROUP; CATION TRANSPORT PROTEINS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; GPI-LINKED PROTEINS; HEMOCHROMATOSIS; HEMOCHROMATOSIS PROTEIN; HEPCIDINS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IRON OVERLOAD; MALE; MUTATION; RECEPTORS, TRANSFERRIN;

EID: 84975081908     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2015.140     Document Type: Article

References (40)

1. Darshan D, Frazer DM, Anderson GJ. Molecular basis of iron-loading disorders. Expert Rev Mol Med 2010; 12: e36
2. Wallace DF, Subramaniam VN. Non-HFE haemochromatosis. World J Gastroenterol 2007; 13: 4690-4698
3. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408
4. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999; 116: 193-207
5. Lucotte G, Dieterlen F. A European allele map of the C282Y mutation of hemochromatosis: Celtic versus Viking origin of the mutation? Blood Cells Mol Dis 2003; 31: 262-267
6. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275-278
7. Beutler E. The significance of the 187G (H63D) mutation in hemochromatosis. Am J Hum Genet 1997; 61: 762-764
8. Walsh A, Dixon JL, Ramm GA, et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006; 4: 1403-1410
9. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093
10. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-Associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003; 361: 669-673
11. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77-82
12. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33: 21-22
13. Camaschella C, Roetto A, Calì A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14-15
14. Mayr R, Janecke AR, Schranz M, et al. Ferroportin disease: a systematic metaanalysis of clinical and molecular findings. J Hepatol 2010; 53: 941-949
15. The 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-1073
16. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-Throughput sequencing data. Nucleic Acids Res 2010; 38: e164
17. Adams PC, Reboussin DM, Barton JC, et al.; Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769-1778
18. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221-230
19. Sánchez M, Villa M, Ingelmo M, et al. Population screening for hemochromatosis: a study in 5370 Spanish blood donors. J Hepatol 2003; 38: 745-750
20. Piperno A, Sampietro M, Pietrangelo A, et al. Heterogeneity of hemochromatosis in Italy. Gastroenterology 1998; 114: 996-1002
21. McDonald CJ, Wallace DF, Crawford DH, Subramaniam VN. Iron storage disease in Asia-Pacific populations: the importance of non-HFE mutations. J Gastroenterol Hepatol 2013; 28: 1087-1094
22. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G-A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211-218
23. Zaahl MG, Merryweather-Clarke AT, Kotze MJ, van der Merwe S, Warnich L, Robson KJ. Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload. Hum Genet 2004; 115: 409-417
24. Lee PL, Gaasterland T, Barton JC. Mild iron overload in an African American man with SLC40A1 D270V. Acta Haematol 2012; 128: 28-32
25. Rice AE, Mendez MJ, Hokanson CA, Rees DC, Björkman PJ. Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter. J Mol Biol 2009; 386: 717-732
26. Le Lan C, Mosser A, Ropert M, et al. Sex and acquired cofactors determine phenotypes of ferroportin disease. Gastroenterology 2011; 140: 1199-1207.e1
27. Cunat S, Giansily-Blaizot M, Bismuth M, et al.; CHU Montpellier AOI 2004 Working Group. Global sequencing approach for characterizing the molecular background of hereditary iron disorders. Clin Chem 2007; 53: 2060-2069
28. Del-Castillo-Rueda A, Moreno-Carralero MI, Cuadrado-Grande N, et al. Mutations in the HFE, TFR2 and SLC40A1 genes in patients with hemochromatosis. Gene 2012; 508: 15-20
29. Bach V, Remacha A, Altés A, Barceló MJ, Molina MA, Baiget M. Autosomal dominant hereditary hemochromatosis associated with two novel Ferroportin 1 mutations in Spain. Blood Cells Mol Dis 2006; 36: 41-45
30. Callebaut I, Joubrel R, Pissard S, et al. Comprehensive functional annotation of 18 missense mutations found in suspected hemochromatosis type 4 patients. Hum Mol Genet 2014; 23: 4479-4490
31. Santos PC, Cançado RD, Pereira AC, et al. Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients. Blood Cells Mol Dis 2011; 46: 302-307
32. Cremonesi L, Forni GL, Soriani N, et al. Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol. 2005; 131: 663-670
33. Lee PL, Gelbart T, West C, Barton JC. SLC40A1 c.1402G-A results in aberrant splicing, ferroportin truncation after glycine 330 and an autosomal dominant hemochromatosis phenotype. Acta Haematol 2007; 118: 237-241
34. Unal S, Piperno A, Gumruk F. Iron chelation with deferasirox in a patient with de-novo ferroportin mutation. J Trace Elem Med Biol 2015; 30: 1-3
35. Lam HY, Clark MJ, Chen R, et al. Performance comparison of whole-genome sequencing platforms. Nat Biotechnol 2012; 30: 78-82
36. Merryweather-Clarke AT, Cadet E, Bomford A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003; 12: 2241-2247
37. De Castro M, Johnston J, Biesecker L. Determining the prevalence of McArdle disease from gene frequency by analysis of next-generation sequencing data. Genet Med 2015; e-pub-Ahead of print 5 March 2015
38. Emond MJ, Louie T, Emerson J, et al.; National Heart, Lung and Blood Institute (NHLBI) GO Exome Sequencing Project; Lung GO. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet 2012; 44: 886-889
39. Hetet G, Elbaz A, Gariepy J, et al. Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases. Eur J Clin Invest 2001; 31: 382-388
40. Rong Y, Bao W, Rong S, et al. Hemochromatosis gene (HFE) polymorphisms and risk of type 2 diabetes mellitus: a meta-Analysis. Am J Epidemiol 2012; 176: 461-472